Sunshine Biopharma, Inc.

SBFM

US8677816014

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
0.8924 ^USD	-0.79%		+2.45%	-96.71%

May. 13	Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-MAY-2024.	CI
Apr. 19	Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	MT

SUNSHINE BIOPHARMA, INC : Other Events (form 8-K)

February 13, 2023 at 02:59 pm EST

Item 8.01 Other Events.

On February 9, 2023, Sunshine Biopharma, Inc. (the "Company") received notice from the Nasdaq Listing Qualifications Staff (the "Staff") that the Staff has determined that the Company has regained compliance with Nasdaq's minimum $1 bid price per share requirement.

Latest news about Sunshine Biopharma, Inc.

Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-MAY-2024.	May. 12	CI
Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	Apr. 19	MT
Top Premarket Decliners	Apr. 19	MT
Sunshine Biopharma Shares Slump After Reverse Stock Split Announcement	Apr. 12	MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	Mar. 28	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Sunshine Biopharma, Inc. announced that it has received $5 million in funding	Mar. 27	CI
Sunshine Biopharma, Inc. announced that it expects to receive $0.01 million in funding	Mar. 03	CI
Sunshine Biopharma, Inc. Announces Executive Changes	Jan. 30	CI
Sunshine Biopharma, Inc. Announces Move Its Headquarters to New York City	Dec. 04	CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	Nov. 13	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Jewish General Hospital Announces Termination of the Research Agreement with Sunshine Biopharma, Inc	Nov. 02	CI
Sunshine Biopharma Gets Extension to Comply With Nasdaq Minimum Bid Price Rule	23-09-22	MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	23-08-10	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60	23-08-07	MT
Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding	23-05-15	CI
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected	23-05-12	MT
Sunshine Biopharma, Inc. announced that it expects to receive CAD 5 million in funding	23-05-11	CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	23-05-10	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-04	CI
Sunshine Biopharma, Inc. Signs Exclusive Worldwide License with University of Arizona for PLpro-Based Covid-19 Treatment	23-02-28	CI
Sector Update: Health Care Stocks Rise on Friday	23-02-10	MT

Chart Sunshine Biopharma, Inc.

Duration

Period

More charts

Company Profile

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sunshine Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.98 USD

Average target price

15 USD

Spread / Average Target

+1,430.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUNSHINE BIOPHARMA, INC.	-96.71%	975K
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+29.39%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+14.11%	238B
ROCHE HOLDING AG	-3.03%	210B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals